High Survival from Severe Combined Immunodeficiency with Screening Programs

This article originally appeared here.
High Survival from Severe Combined Immunodeficiency with Screening Programs
High Survival from Severe Combined Immunodeficiency with Screening Programs

(HealthDay News) — Newborn screening programs in the United States have identified severe combined immunodeficiency (SCID) in one in 58,000, with high survival seen in SCID-affected infants, according to a study published in the August 20 issue of the Journal of the American Medical Association.

Antonia Kwan, PhD, from the University of California in San Francisco, and colleagues presented data from a spectrum of SCID newborn screening programs to establish the population-based incidence of SCID. Data were submitted for 3,030,083 newborns from 10 states, screened with assays to detect T-cell receptor excision circles.

The researchers found that 52 cases of typical SCID, leaky SCID, and Omenn syndrome were detected with screening, affecting one in 58,000 infants. Through diagnosis and immune reconstitution, survival of SCID-affected infants was 87%, and survival was 92% for infants who received transplantation, enzyme replacement, and/or gene therapy. Immunoglobulin infusions, preventative antibiotics, and avoidance of live vaccines were additional interventions for SCID and non-SCID T-cell lymphopenia. The rates of detection of non-SCID T-cell lymphopenia were influenced by variations in definitions and follow-up practices.

"Newborn screening in 11 programs in the United States identified SCID in one in 58 000 infants, with high survival," the authors write. "The usefulness of detection of non-SCID T-cell lymphopenias by the same screening remains to be determined."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)